Mycophenolate mofetil therapy reduces the risk of relapse in people with myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disorders.
Why this matters
In the absence of clinically proven prophylactic long-term treatments, these findings provide class IV evidence that mycophenolate mofetil therapy may prevent relapse in people with myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disorders.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.